Table 2. Multivariate analysis for survival.

Covariant	References	Intravesical recurrence-free survival				Recurrence-free survival				Cancer-specific survival				Overall survival
		HR	95% CI	P value		HR	95% CI	P value		HR	95% CI	P value		HR	95% CI	P value
Age (continuous)		1.01	0.98–1.03	0.47		0.99	0.97–1.02	0.6		1.04	1.01–1.07	0.005		1.04	1.02–1.07	0.002
Sex
Female	Male	0.51	0.31–0.83	0.008		1.11	0.76–1.63	0.58		0.82	0.49–1.36	0.43		0.65	0.40–1.04	0.075
Charlson comorbidity index
≥2	0–1	1.9	0.85–4.25	0.12		1.89	0.89–4.02	0.096		1.4	0.55–3.60	0.48		1.65	0.74–3.67	0.22
Tumor location
Ureter	Renal pelvis	1.69	0.94–3.06	0.08		1.06	0.68–1.66	0.8		0.95	0.54–1.64	0.84		0.97	0.58–1.61	0.9
Both		2.43	1.17–5.06	0.017		1.04	0.49–2.21	0.92		0.73	0.24–2.18	0.57		0.93	0.37–2.31	0.87
Hydronephrosis
Present	Absent	0.53	0.32–0.89	0.015		0.91	0.59–1.40	0.67		0.86	0.50–1.47	0.57		0.85	0.52–1.38	0.51
Pathological T stage
≥ pT3	≤ pT2	0.81	0.46–1.42	0.46		2.12	1.19–3.81	0.011		2.33	1.13–4.82	0.022		2.08	1.10–3.96	0.025
Histology
UC with variant histology	Pure UC	0.84	0.36–1.97	0.69		1.46	0.80–2.67	0.22		1.56	0.72–3.39	0.26		1.63	0.89–3.01	0.12
Lymph node status
pN1–2	pN0	0.82	0.33–2.06	0.68		2.06	1.17–3.62	0.012		2.42	1.24–4.74	0.01		2.58	1.40–4.75	0.002
pNx		1.22	0.78–1.93	0.39		0.98	0.65–1.47	0.91		0.98	0.58–1.64	0.93		1.05	0.65–1.67	0.85
Concomitant CIS
Present	Absent	1.26	0.73–2.18	0.41		0.77	0.46–1.29	0.32		0.48	0.22–1.03	0.06		0.61	0.32–1.15	0.12
LVI
Present	Absent	1.44	0.91–2.26	0.12		2.68	1.77–4.06	0.001		2.21	1.33–3.67	0.002		2.57	1.61–4.11	0.001
Adjuvant chemotherapy
Present	Absent	0.44	0.26–0.77	0.004		0.87	0.58–1.30	0.49		1.3	0.80–2.14	0.29		1.18	0.75–1.84	0.48

HR, hazard ratio; CI, confidence interval; UC, urothelial carcinoma; CIS, carcinoma in situ; LVI, lymphovascular invasion.